Marco De Amici

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2507644/publications.pdf

Version: 2024-02-01

96 2,307 25 42 papers citations h-index g-index

99 99 99 2188
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells. Cells, 2021, 10, 1877.	4.1	8
2	Synthesis and characterization of 13C labeled carnosine derivatives for isotope dilution mass spectrometry measurements in biological matrices. Talanta, 2021, 235, 122742.	5. 5	2
3	2020 Italian Special Anniversary Collection: Celebrating NMMC 2019 and 40 Years of the DCF‧CI. ChemMedChem, 2021, 16, 303-308.	3.2	1
4	The Mechanisms Mediated by $\hat{l}_{\pm}7$ Acetylcholine Nicotinic Receptors May Contribute to Peripheral Nerve Regeneration. Molecules, 2021, 26, 7668.	3.8	7
5	Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M1 muscarinic acetylcholine receptors. Bioorganic Chemistry, 2020, 96, 103633.	4.1	10
6	Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation. European Journal of Medicinal Chemistry, 2020, 205, 112669.	5 . 5	12
7	Ligand-Specific Allosteric Coupling Controls G-Protein-Coupled Receptor Signaling. ACS Pharmacology and Translational Science, 2020, 3, 859-867.	4.9	15
8	Novel analgesic agents obtained by molecular hybridization of orthosteric and allosteric ligands. European Journal of Pharmacology, 2020, 876, 173061.	3.5	3
9	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. Biochemical Pharmacology, 2019, 163, 154-168.	4.4	14
10	In vivo and in vitro ADMET profiling and in vivo pharmacodynamic investigations of a selective $\hat{l}\pm7$ nicotinic acetylcholine receptor agonist with a spirocyclic \hat{l} 2 -isoxazoline molecular skeleton. European Journal of Pharmacology, 2018, 820, 265-273.	3.5	12
11	Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells. Neurochemistry International, 2018, 118, 52-60.	3.8	19
12	Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the $\hat{l}\pm7$ nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation. European Journal of Medicinal Chemistry, 2018, 160, 207-228.	5.5	9
13	A Small Library of 1,2,3â€Triazole Analogs of <scp>CAP</scp> â€55: Synthesis and Binding Affinity at Nicotinic Acetylcholine Receptors. Chemistry and Biodiversity, 2018, 15, e1800210.	2.1	5
14	A New Molecular Mechanism To Engineer Protean Agonism at a G Protein–Coupled Receptor. Molecular Pharmacology, 2017, 91, 348-356.	2.3	13
15	Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M ₁ and M ₂ . MedChemComm, 2017, 8, 1346-1359.	3.4	10
16	Insight into the Mechanism of Hydrolysis of Meropenem by OXA-23 Serine- \hat{l}^2 -lactamase Gained by Quantum Mechanics/Molecular Mechanics Calculations. Biochemistry, 2016, 55, 5191-5200.	2.5	13
17	Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor. Journal of Biological Chemistry, 2016, 291, 16375-16389.	3.4	67
18	Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the $\hat{1}\pm3\hat{1}^24$ nicotinic acetylcholine receptor subtype. European Journal of Medicinal Chemistry, 2016, 108, 392-405.	5.5	14

#	Article	IF	Citations
19	Allosteric Modulation of Alpha7 Nicotinic Receptors: Mechanistic Insight through Metadynamics and Essential Dynamics. Journal of Chemical Information and Modeling, 2015, 55, 2528-2539.	5.4	11
20	Bifunctional compounds targeting both D2 and non- $\hat{l}\pm7$ nACh receptors: Design, synthesis and pharmacological characterization. European Journal of Medicinal Chemistry, 2015, 101, 367-383.	5 . 5	12
21	On the selection of an opioid for local skin analgesia: Structure-skin permeability relationships. International Journal of Pharmaceutics, 2015, 489, 177-185.	5. 2	14
22	A convenient synthesis of 4-(2-hydroxyethyl)indolin-2-one, a useful intermediate for the preparation of both dopamine receptor agonists and protein kinase inhibitors. Monatshefte FÃ $\frac{1}{4}$ r Chemie, 2014, 145, 1139-1144.	1.8	1
23	Dynamic ligand binding dictates partial agonism at a G protein–coupled receptor. Nature Chemical Biology, 2014, 10, 18-20.	8.0	45
24	Inactivation of TEM-1 by Avibactam (NXL-104): Insights from Quantum Mechanics/Molecular Mechanics Metadynamics Simulations. Biochemistry, 2014, 53, 5174-5185.	2.5	30
25	Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: Synthesis, inÂvitro functional characterization, and inÂvivo evaluation of their analgesic activity. European Journal of Medicinal Chemistry, 2014, 75, 222-232.	5.5	25
26	Involvement of $\hat{l}\pm 7$ nAChR subtype in rat oxaliplatin-induced neuropathy: Effects of selective activation. Neuropharmacology, 2014, 79, 37-48.	4.1	75
27	New insight into active muscarinic receptors with the novel radioagonist [3H]iperoxo. Biochemical Pharmacology, 2014, 90, 307-319.	4.4	16
28	Investigating the hydrogen-bond acceptor site of the nicotinic pharmacophore model: a computational and experimental study using epibatidine-related molecular probes. Journal of Computer-Aided Molecular Design, 2013, 27, 975-987.	2.9	7
29	The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nature Communications, 2012, 3, 1044.	12.8	117
30	A novel spirocyclic tropanyl-l"2-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake. Bioorganic and Medicinal Chemistry, 2012, 20, 6344-6355.	3.0	7
31	The enantiomers of epiboxidine and of two related analogs: Synthesis and estimation of their binding affinity at $\hat{l}\pm4\hat{l}^22$ and $\hat{l}\pm7$ neuronal nicotinic acetylcholine receptors. Chirality, 2012, 24, 543-551.	2.6	5
32	Synthesis and binding affinity at $\hat{l}\pm4\hat{l}^22$ and $\hat{l}\pm7$ nicotinic acetylcholine receptors of new analogs of epibatidine and epiboxidine containing the 7-azabicyclo[2.2.1]hept-2-ene ring system. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 829-832.	2.2	11
33	New spirocyclic \hat{l} 2-isoxazoline derivatives related to selective agonists of $\hat{l}\pm 7$ neuronal nicotinic acetylcholine receptors. European Journal of Medicinal Chemistry, 2011, 46, 5790-5799.	5 . 5	12
34	Design, Synthesis, and Pharmacological Characterization of Novel Spirocyclic Quinuclidinylâ€Î" ² â€Isoxazoline Derivatives as Potent and Selective Agonists of α7 Nicotinic Acetylcholine Receptors. ChemMedChem, 2011, 6, 889-903.	3.2	32
35	Engineering of αâ€conotoxin Mllâ€derived peptides with increased selectivity for native α6β2 â^— nicotinic acetylcholine receptors. FASEB Journal, 2011, 25, 3775-3789.	0.5	32
36	Determination of Acid Dissociation Constants of Compounds Active at Neuronal Nicotinic Acetylcholine Receptors by Means of Electrophoretic and Potentiometric Techniques. Analytical Sciences, 2010, 26, 51-54.	1.6	23

#	Article	IF	Citations
37	Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal Research Reviews, 2010, 30, 463-549.	10.5	88
38	Novel tricyclic Î"2-isoxazoline and 3-oxo-2-methyl-isoxazolidine derivatives: Synthesis and binding affinity at neuronal nicotinic acetylcholine receptor subtypes. Bioorganic and Medicinal Chemistry, 2010, 18, 4498-4508.	3.0	16
39	Rational design of dualsteric GPCR ligands: quests and promise. British Journal of Pharmacology, 2010, 159, 997-1008.	5.4	103
40	Synthesis of novel chiral î"2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. European Journal of Medicinal Chemistry, 2010, 45, 5594-5601.	5.5	13
41	Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB Journal, 2009, 23, 442-450.	0.5	140
42	New Analogues of Epiboxidine Incorporating the 4,5â€Dihydroisoxazole Nucleus: Synthesis, Binding Affinity at Neuronal Nicotinic Acetylcholine Receptors, and Molecular Modeling Investigations. Chemistry and Biodiversity, 2009, 6, 244-259.	2.1	13
43	Design of novel α7-subtype-preferring nicotinic acetylcholine receptor agonists: Application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6353-6357.	2.2	29
44	Alpha7 nicotinic acetylcholine receptor agonists: Prediction of their binding affinity through a molecular mechanics Poisson–Boltzmann surface area approach. Journal of Computational Chemistry, 2008, 29, 2593-2602.	3.3	35
45	Epiboxidine and novel-related analogues: A convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4651-4654.	2.2	28
46	Synthesis of enantiomerically pure HIP-A and HIP-B and investigation of their activity as inhibitors of excitatory amino acid transporters. Tetrahedron: Asymmetry, 2008, 19, 867-875.	1.8	22
47	Synthesis and Pharmacological Characterization at Glutamate Receptors of the Four Enantiopure Isomers of Tricholomic Acid. Journal of Medicinal Chemistry, 2008, 51, 2311-2315.	6.4	30
48	Neuroprotective Effects of the Novel Glutamate Transporter Inhibitor (–)-3-Hydroxy-4,5,6,6 <i>a</i> -tetrahydro-3 <i>aH</i> -pyrrolo[3,4- <i>d</i>]-isoxazole-4-carboxylic Acid, Which Preferentially Inhibits Reverse Transport (Glutamate Release) Compared with Glutamate Reuptake. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 646-656.	2.5	36
49	Synthesis and pharmacological characterization at glutamate receptors of erythro- and threo-tricholomic acid and homologues thereof. Tetrahedron, 2007, 63, 2249-2256.	1.9	18
50	Novel chiral isoxazole derivatives: Synthesis and pharmacological characterization at human β-adrenergic receptor subtypes. Bioorganic and Medicinal Chemistry, 2007, 15, 2533-2543.	3.0	22
51	Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes. Bioorganic and Medicinal Chemistry, 2007, 15, 7626-7637.	3.0	8
52	Design, Synthesis, and Action of Oxotremorine-Related Hybrid-Type Allosteric Modulators of Muscarinic Acetylcholine Receptors. Journal of Medicinal Chemistry, 2006, 49, 366-372.	6.4	71
53	Synthesis of enantiopure \hat{l} 2-isoxazoline derivatives and evaluation of their affinity and efficacy profiles at human \hat{l} 2-adrenergic receptor subtypes. Bioorganic and Medicinal Chemistry, 2006, 14, 4393-4401.	3.0	15
54	Allosteric Modulators and Selective Agonists of Muscarinic Receptors. Journal of Molecular Neuroscience, 2006, 30, 165-168.	2.3	12

#	Article	IF	CITATIONS
55	Synthesis of Epibatidine-Related Δ2-Isoxazoline Derivatives and Evaluation of Their Binding Affinity at Neuronal Nicotinic Acetylcholine Receptors. European Journal of Organic Chemistry, 2006, 2006, 3746-3754.	2.4	14
56	Synthesis of 3-Hydroxy- and 3-Carboxy-î"2-isoxazoline Amino Acids and Evaluation of Their Interaction with GABA Receptors and Transporters. European Journal of Organic Chemistry, 2006, 2006, 5533-5542.	2.4	19
57	Development of a Three-Dimensional Model for theN-Methyl-d-aspartate NR2A Subunit. Journal of Medicinal Chemistry, 2005, 48, 5489-5494.	6.4	9
58	Synthesis, Binding Affinity at Glutamic Acid Receptors, Neuroprotective Effects, and Molecular Modeling Investigation of Novel Dihydroisoxazole Amino Acids. Journal of Medicinal Chemistry, 2005, 48, 6315-6325.	6.4	43
59	Enantiopure stereoisomeric homologues of glutamic acid: chemoenzymatic synthesis and assignment of their absolute configurations. Tetrahedron: Asymmetry, 2004, 15, 3079-3090.	1.8	22
60	Design, Synthesis, and Pharmacological Characterization of Novel, Potent NMDA Receptor Antagonists. Journal of Medicinal Chemistry, 2004, 47, 6740-6748.	6.4	22
61	Synthesis and biological evaluation of new amino acids structurally related to the antitumor agent acivicin. Il Farmaco, 2003, 58, 683-690.	0.9	16
62	Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands. Il Farmaco, 2003, 58, 739-748.	0.9	9
63	Design of Cyclopentaisoxazoline Amino Acids as Conformationally Constrained Agonists at Glutamate Receptors. European Journal of Organic Chemistry, 2003, 2003, 4455-4461.	2.4	6
64	A combinatorial biocatalysis approach to an array of cholic acid derivatives. Biotechnology and Bioengineering, 2003, 81, 391-396.	3.3	26
65	Design of novel conformationally restricted analogues of glutamic acid. Tetrahedron, 2003, 59, 1443-1452.	1.9	11
66	Synthesis and Anticonvulsant Activity of Novel Bicyclic Acidic Amino Acids. Journal of Medicinal Chemistry, 2003, 46, 3102-3108.	6.4	26
67	Evidence for specific analgesic activity of a muscarinic agonist selected among a new series of acetylenic derivatives. Life Sciences, 2001, 68, 1775-1785.	4.3	18
68	\hat{l}^2 3 -Adrenergic receptor ligands: insight into structure \hat{a} = "activity relationships using Monte-Carlo conformational analysis in water. Tetrahedron, 2001, 57, 1849-1855.	1.9	4
69	A chemoenzymatic approach to the synthesis of the stereoisomers of a \hat{l}^2 -adrenergic receptor antagonist. Tetrahedron: Asymmetry, 2000, 11, 2741-2751.	1.8	8
70	Design of new analogues of glutamic acid with a conformationally restricted structure. Il Farmaco, 2000, 55, 162-164.	0.9	3
71	Synthesis and pharmacological characterization of new chiral derivatives of muscarine and allo-muscarine. Il Farmaco, 2000, 55, 535-543.	0.9	5
72	Pharmacological profile of enantiomerically pure chiral muscarinic agonists. Life Sciences, 2000, 67, 317-326.	4.3	2

#	Article	IF	Citations
73	New analogues of oxotremorine and oxotremorine-M. Life Sciences, 2000, 67, 717-723.	4.3	22
74	Synthesis of new bicyclic analogues of glutamic acid. Tetrahedron, 1999, 55, 5623-5634.	1.9	26
75	Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorganic and Medicinal Chemistry, 1999, 7, 1539-1547.	3.0	43
76	Synthesis and Enantiopharmacology of New AMPA-Kainate Receptor Agonists. Journal of Medicinal Chemistry, 1999, 42, 4099-4107.	6.4	42
77	synthesis of new \hat{l} " 2 -isoxazoline derivatives and their pharmacological characterization as \hat{l}^2 -adrenergic receptor antagonists. Bioorganic and Medicinal Chemistry, 1998, 6, 401-408.	3.0	81
78	Chemoenzymatic synthesis of the enantiomers of desoxymuscarine. Tetrahedron: Asymmetry, 1998, 9, 657-665.	1.8	16
79	Synthesis and Pharmacology of a New AMPAâ ⁻ 'Kainate Receptor Agonist with Potent Convulsant Activity. Journal of Medicinal Chemistry, 1998, 41, 3759-3762.	6.4	11
80	Synthesis and Pharmacological Characterization of Enantiomerically Pure Muscarinic Agonists: Difluoromuscarines. Journal of Medicinal Chemistry, 1997, 40, 1099-1103.	6.4	15
81	Synthesis and binding affinity of new muscarinic ligands structurally related to oxotremorine. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1033-1036.	2.2	8
82	Nitrile oxides in medicinal chemistry. 6. Enzymatic resolution of a set of bicyclic \hat{l} 2-isoxazolines. Tetrahedron: Asymmetry, 1996, 7, 787-796.	1.8	11
83	Chiral separation of muscarinic antagonists by capillary zone electrophoresis with cyclodextrin additives. Journal of Chromatography A, 1996, 741, 287-294.	3.7	9
84	Nitrile oxides in medicinal chemistry. 5. Lipase PS-catalyzed resolution of a set of heterocyclic derivatives Tetrahedron: Asymmetry, 1993, 4, 1063-1072.	1.8	22
85	Chemoenzymatic synthesis of acetyl (R)-(+)- and (S)-(\hat{a} °)-cycloserine. Tetrahedron: Asymmetry, 1993, 4, 1073-1080.	1.8	9
86	Synthesis and pharmacological investigation of the enantiomers of muscarone and allo-muscarone. Journal of Medicinal Chemistry, 1992, 35, 1915-1920.	6.4	22
87	Synthesis and pharmacological investigation of stereoisomeric muscarines. Chirality, 1992, 4, 230-239.	2.6	12
88	Further Characterization of the Solid Forms of Iopanoic Acid and its Enantiomers. Archiv Der Pharmazie, 1992, 325, 385-388.	4.1	3
89	Chemoenzymic synthesis of the eight stereoisomeric muscarines. Journal of Organic Chemistry, 1991, 56, 67-72.	3.2	56
90	Nitrile oxides in medicinal chemistry-2. synthesis of the two enantiomers of dihydromuscimol. Tetrahedron, 1990, 46, 1975-1986.	1.9	79

#	ARTICLE	IF	CITATION
91	Synthesis and pharmacological investigation of cholinergic ligands structurally related to muscarone. European Journal of Medicinal Chemistry, 1989, 24, 171-177.	5.5	21
92	Stereoselectivities of mesitonitrile oxide cycloadditions to 7-substituted norbornadienes. Tetrahedron Letters, 1989, 30, 807-810.	1.4	14
93	Chemoenzymatic synthesis of chiral isoxazole derivatives. Journal of Organic Chemistry, 1989, 54, 2646-2650.	3.2	81
94	Synthesis and pharmacological investigation of the 3-analogs of viminol. European Journal of Medicinal Chemistry, 1988, 23, 511-515.	5.5	4
95	Metal-hydride reduction of isoxazoline-3-carboxylate esters. Tetrahedron, 1986, 42, 5267-5272.	1.9	18
96	Synthesis of hentriacontane-14,16-dione, a \hat{l}^2 -diketone found in plant waxes. Journal of the Chemical Society Chemical Communications, 1978, .	2.0	11